{"id":39282,"date":"2021-04-28T14:12:29","date_gmt":"2021-04-28T14:12:29","guid":{"rendered":"https:\/\/setterwalls.se\/case\/setterwalls-has-advised-wntresearch-in-connection-with-rights-issue\/"},"modified":"2022-02-14T13:44:07","modified_gmt":"2022-02-14T13:44:07","slug":"setterwalls-has-advised-wntresearch-in-connection-with-rights-issue","status":"publish","type":"assignments","link":"https:\/\/setterwalls.se\/en\/case\/setterwalls-has-advised-wntresearch-in-connection-with-rights-issue\/","title":{"rendered":"Setterwalls has advised WntResearch in connection with rights issue"},"content":{"rendered":"<p><strong>Setterwalls has advised WntResearch AB in connection with a rights issue of units, consisting of shares and warrants.<\/strong><\/p>\n<p>WntResearch AB is a biotech company in oncology conducting development of drug candidates with a focus on various forms of metastatic cancer. The company\u2019s research is focused on studying the body-specific protein WNT5A, which has shown to affect the spread of tumor cells. The company\u2019s main pharmaceutical candidate is Foxy-5 \u2013 a phase II drug candidate that is considered to have great potential in the treatment against tumor spread.<\/p>\n<p>Through the rights issue, WntResearch AB receives cash issue proceeds of approximately SEK 56.4 million before issue costs. In addition, WntResearch AB may receive additional issue proceeds of a maximum of approximately SEK 85 million before issue costs, provided that all warrants issued in connection with the rights issue are exercised for subscription of new shares in the company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Setterwalls has advised WntResearch AB in connection with a rights issue of units, consisting of shares and warrants.<\/strong><\/p>\n<p>WntResearch AB is a biotech company in oncology conducting development of drug candidates with a focus on various forms of metastatic cancer. The company\u2019s research is focused on studying the body-specific protein WNT5A, which has shown to affect the spread of tumor cells. The company\u2019s main pharmaceutical candidate is Foxy-5 \u2013 a phase II drug candidate that is considered to have great potential in the treatment against tumor spread.<\/p>\n<p>Through the rights issue, WntResearch AB receives cash issue proceeds of approximately SEK 56.4 million before issue costs. In addition, WntResearch AB may receive additional issue proceeds of a maximum of approximately SEK 85 million before issue costs, provided that all warrants issued in connection with the rights issue are exercised for subscription of new shares in the company.<\/p>\n","protected":false},"author":1,"featured_media":33993,"template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":""},"class_list":["post-39282","assignments","type-assignments","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments\/39282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments"}],"about":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/types\/assignments"}],"author":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media\/33993"}],"wp:attachment":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media?parent=39282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}